NDI notifications: when you need one (and the 2026 FDA guidance)

Want to use an innovative ingredient in a US supplement — something new, recently developed, or made by a novel process? Before you build it into a product, there is a question that can stop a launch cold: does it need a New Dietary Ingredient notification? It is the closest thing the US has to a pre-market gate for supplement ingredients, and in 2026 it is squarely in the spotlight.

What an NDI is

Under US law, a new dietary ingredient is, broadly, a dietary ingredient that was not marketed in the United States before October 15, 1994. The date is the dividing line: ingredients with a US marketing history before then are treated differently from those introduced after.

If an ingredient is new in this sense — and is not present in the food supply in an unaltered form — the manufacturer may be required to submit a notification to the FDA, with evidence supporting the ingredient's safety, before marketing a supplement containing it.

A notification, not an approval

An NDI notification is not an approval. The manufacturer submits safety information; the FDA reviews it within a set period (commonly described as a 75-day window) and may object, raise questions, or let the period pass. The responsibility for the ingredient's safety remains with the manufacturer, but the notification gives the agency a chance to weigh in before the product is sold.

It is a genuine pre-market step within an otherwise post-market system — which is why getting the NDI question right early matters so much.

When you need one — and when you may not

The analysis turns on the ingredient's history and nature. An ingredient marketed in the US before the cut-off, or present in the food supply in an unaltered form, generally does not trigger the notification. A genuinely new ingredient, or one made by a new process that alters it, may.

The grey areas — synthetic versions of natural substances, new production methods, novel sources — are exactly where the debate is liveliest, and where careful analysis is needed before formulating.

Why it is in the spotlight in 2026

The NDI process has long been a source of uncertainty, and the FDA has committed to finalising updated NDI guidance. At the same time, the agency has been re-examining the very definition of a dietary ingredient as biotechnology and novel production methods produce substances that did not exist when the rules were written. Manufacturers should expect the NDI landscape to keep moving.

Because NDI guidance and the underlying definitions are actively being updated, confirm the current FDA position for your specific ingredient rather than relying on a general summary.

The parallel with EU Novel Food

Manufacturers who know the EU will recognise the shape of this: like the EU's Novel Food rules, the NDI system turns on whether an ingredient has a relevant history of use, and treats genuinely new ingredients as something to clear before market. The frameworks differ in their detail and their cut-offs, but the instinct is the same — check the status of a new ingredient before you design a product around it.

Building the check in early

The expensive mistake is the same one Novel Food causes in the EU: formulating around an ingredient, then discovering late that it needed an NDI notification it does not have. The fix is to treat ingredient status as a first-step question — flagged when the ingredient is added to a formula — so a notification-triggering ingredient surfaces before development effort goes in.

When the NDI-relevant status travels with the ingredient, the can-we-even-use-this-yet question is answered up front.

The takeaway

An NDI notification is the US pre-market step for genuinely new supplement ingredients, turning on a 1994 cut-off and the ingredient's nature, reviewed by the FDA before marketing. With the rules being updated and the definition of a dietary ingredient under active review, the discipline is to check NDI status at the start of formulation — not after a product is built around an ingredient that cannot yet be sold.

Lemoniq surfaces ingredient status as you formulate, so an ingredient that may need an NDI notification is flagged before development starts — the same way it handles novel status for other markets. We solve this exact problem. See how it works